Theriva BiologicsTOVX
13F holders, Q3 2025 (September 30)20holders +3
7new positions
4sold out
$0.41avg. 13F price*
At the end of Q3 2025, 20 institutions reported holding Theriva Biologics Inc. (TOVX) in their 13F filings, up 3 from Q2 2025. 7 opened new positions and 4 sold out. The largest holders were Ikarian Capital, LLC ($49K), Two Sigma Investments, LP ($25K) and Virtu Financial LLC ($15K).
- Company
- Theriva Biologics Inc.
- CUSIP
- 87164U508
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 7 | $62K |
| Exits | 4 | $25K |
All 13F filers, Q2 2025 → Q3 2025: 202,944 shares bought and 56,903 shares sold, net +146,041 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 20 holders
| Ikarian Capital, LLC | 0.01% | No change | 120,031 | $49K |
| Two Sigma Investments, LP | 0.00% | New | 61,837 | $25K |
| Virtu Financial LLC | 0.00% | Add +6.6% | 36,781 | $15K |
| Jane Street Group, LLC | 0.00% | New | 36,771 | $15K |
| Boothbay Fund Management, LLC | 0.00% | No change | 35,601 | $14K |
| XTX Topco Ltd | 0.00% | Add +91.4% | 32,899 | $13K |
| Geode Capital Management, LLC | 0.00% | Add +51.6% | 28,209 | $11K |
| Two Sigma Advisers, LP | 0.00% | New | 27,284 | $11K |
| UBS Group AG | 0.00% | Add +2291200.0% | 22,913 | $9K |
| Vanguard Group Inc. | 0.00% | New | 16,382 | $7K |
| HRT Financial LP | 0.00% | New | 10,142 | $4K |
| BlackRock, Inc. | 0.00% | Reduce -0.8% | 7,506 | $3K |
| Osaic Holdings, Inc. | 0.00% | No change | 444 | $172 |
| Clear Street Group Inc. | 0.00% | — | 100 | $41 |
| Bank of America Corp. | 0.00% | Add +9.5% | 81 | $32 |
| SBI Securities Co., Ltd. | 0.00% | Reduce -1.7% | 59 | $24 |
| IFP Advisors, Inc | 0.00% | No change | 11 | $4 |
| Wealthspire Advisors, LLC | 0.00% | New | 2 | $1 |
| Danske Bank A/S | 0.00% | No change | 1 | $0 |
| Citigroup Inc. | 0.00% | New | 1 | $0 |
"% of holder's portfolio" is TOVX's weight in each manager's 13F, not the share of Theriva Biologics Inc. the manager owns.